An observational study in Urinary Urge Incontinence, sponsored by Neuspera Medical, Inc.. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Neuspera Medical, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 6th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 18 of the 25 other live ones, and was the 133rd registered.
243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.
Browse Urinary Incontinence, Urge studies →19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18–89
Axonics, Inc. · Sites in United States, Australia
Ages 18+
MedtronicNeuro · Sites in United States
Ages 18+
InMode MD Ltd. · Sites in United States
Ages 22–80 · Women only
Neuspera Medical, Inc. · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 14 · Phase 4 19
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 133 across 39 observational studies indexed under Urinary Incontinence, Urge.
Median enrollment 75 across the 119 interventional studies, 47 across the 15 observational. Of the 97 that completed or were terminated, 51 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 135 have an industry lead sponsor. The 10 most frequent:
Neuspera Medical, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Neuspera Medical, Inc. has 2 studies filed under Urinary Incontinence, Urge — fewer than ten, so there is no comparison to draw.
11 of the studies in Urinary Incontinence, Urge with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT07335484Axonics, Inc.Aquarius Pilot Study to Evaluate the New Axonics Trial System | 2026-11 |
| NCT07247136Neuspera Medical, Inc.Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System | 2026-11 |
| NCT06186765Axonics, Inc.F15 Recharge Free Axonics SNM System Clinical Study | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Single-arm study where subjects' responses to a questionnaire for the traditional Sacral Neuromodulation (SNM) devices will be compared to the responses regarding the Neuspera SNM System.
Subjects will be enrolled in a single-arm study and followed for 1-month after implant of the Neuspera SNM System.
Subjects will complete a questionnaire regarding their experience with the traditional SNM system prior to the Neuspera implant, then undergo an implant of the Neuspera SNM system using standard of care according to the device's commercial labeling.
Up to 20 subjects will be enrolled.
Study population with 22 years of age or older and who have or have previously had a traditional SNM system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with previous traditional SNM system and now undergoing implant of the Neuspera SNM System
Device: Neuspera Implantable Sacral Neuromodulation System
Stimulation of the Sacral Nerve
Subject Questionnaire
The changes to subject questionnaire responses for the Neuspera SNM system compared to responses regarding traditional SNM systems.
Time frame: 1 month
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 19 observational studies under Urinary Incontinence, Urge, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 45. This study's planned 12 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Mar 2026 → Apr 2026, primary completion Oct 2026 → Apr 2027 and completion Oct 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neuspera Medical, Inc.